Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Duchenne News Tags: Avidity Biosciences

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco ITF Therapeutics NS Pharma PepGen Percheron Therapeutics Pfizer Pliant Therapeutics Precision Biosciences PTC Therapeutics REGENXBIO Roche Santhera Sarepta Therapeutics Satellos Bioscience Solid Biosciences Upsher-Smith Wave Life Sciences
December 13, 2023

Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy

Avidity shares an update on positive AOC 1044 data in healthy volunteers from the Phase 1/2 EXPLORE44™ clinical trial.
Read More
May 9, 2023

Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1

Avidity announces positive topline data from the Phase 1/2 MARINA™ clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1
Read More
April 24, 2023

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Mutations Amenable to Exon 44 Skipping

Avidity announces Fast Track designation to AOC 1044 for the treatment of Duchenne
Read More
March 20, 2023

Avidity Provides Update on AOC 1001 Program in Myotonic Dystrophy Type 1

Avidity Biosciences provides an update on the Phase 1/2 MARINA™ trial of AOC 1001 in adults with myotonic dystrophy type 1.
Read More
December 14, 2022

Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle

Avidity announces positive AOC 1001 date from preliminary MARINA study assessment
Read More